These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

620 related items for PubMed ID: 22228235

  • 1. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants.
    Vesikari T, Prymula R, Schuster V, Tejedor JC, Cohen R, Bouckenooghe A, Damaso S, Han HH.
    Pediatr Infect Dis J; 2012 May; 31(5):509-13. PubMed ID: 22228235
    [Abstract] [Full Text] [Related]

  • 2. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.
    Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV, Han HH, ROTA-054 Study Group.
    Pediatr Infect Dis J; 2012 May; 31(5):487-93. PubMed ID: 22228231
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of the oral pentavalent rotavirus vaccine in Mali.
    Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU, Lewis KD, Victor JC, Steele AD, Neuzil KM, Kotloff KL, Levine MM.
    Vaccine; 2012 Apr 27; 30 Suppl 1():A71-8. PubMed ID: 22520140
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, De Vos B, Bock HL.
    J Infect Dis; 2005 Sep 01; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
    Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM, Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group.
    Pediatrics; 2007 Jan 01; 119(1):11-8. PubMed ID: 17200266
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.
    Vesikari T, Karvonen A, Bouckenooghe A, Suryakiran PV, Smolenov I, Han HH.
    Vaccine; 2011 Mar 03; 29(11):2079-84. PubMed ID: 21238572
    [Abstract] [Full Text] [Related]

  • 10. Update on Rotarix: an oral human rotavirus vaccine.
    O'Ryan M, Linhares AC.
    Expert Rev Vaccines; 2009 Dec 03; 8(12):1627-41. PubMed ID: 19943758
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial.
    Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, Neuzil KM, Steele AD.
    Vaccine; 2012 Apr 27; 30 Suppl 1():A44-51. PubMed ID: 22520136
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.
    Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM.
    Lancet; 2010 Aug 21; 376(9741):606-14. PubMed ID: 20692030
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials.
    De Vos B, Han HH, Bouckenooghe A, Debrus S, Gillard P, Ward R, Cheuvart B.
    Pediatr Infect Dis J; 2009 Apr 21; 28(4):261-6. PubMed ID: 19289978
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children. US Rotavirus Vaccine Efficacy Group.
    Rennels MB, Wasserman SS, Glass RI, Keane VA.
    Pediatrics; 1995 Dec 21; 96(6):1132-6. PubMed ID: 7491235
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
    Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, Neuzil KM, Breiman RF.
    Vaccine; 2012 Apr 27; 30 Suppl 1():A52-60. PubMed ID: 22520137
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.
    Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ, REST Study Team.
    Pediatr Infect Dis J; 2007 Dec 27; 26(12):1099-104. PubMed ID: 18043445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.